PRRT

We get a lot of questions about Peptide Receptor Radionuclide Therapy (PRRT). This is a list of questions answered by Dawn Marie about her personal experience with PRRT. What to take with? Some say hardly anything because of the radioactive. They kept me hospitalized in Europe for several days because of the radiation levels. Here in the U.S., I understand that they send you home the same day. So, I

M. Sue O'Dorisio

University of Iowa Holden Comprehensive Cancer Center is the first U.S. cancer center to be designated a Neuroendocrine Tumor Center of Excellence by the European Neuroendocrine Tumor Society (ENETS). In making the award to the Iowa team in early March, ENETS listed its criteria for the distinction, including The Holden team’s advanced interdisciplinary approach for diagnosing neuroendocrine tumor (NET) patients The quality and breadth of the team’s medical treatments for NETS

PRRT is finally approved in the U.S.

After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients with neuroendocrine tumors. The approval comes at a time when incidence of neuroendocrine cancers of the pancreas, lungs, and intestines are on the rise. About 7 in 100,000 people are

Dr. Thor & Dr. Tuba present The Future of PRRT & The Team Approach

On January 14, 2018, Dr. Thor Halfdanarson and Dr. A. Tuba Kendi from Mayo Clinic Rochester presented to Northwoods NETS. Dr. Tuba, a radiologist from Mayo, has been fronting the Gallium-68 PET/MRI scan center that has been helping detect and diagnose neuroendocrine tumor patients. She is now at the forefront the PRRT (peptide receptor radionuclide therapy) at the Rochester clinic. Dr. Thor presented his vision for the newly designated Neuroendocrine

Part Twelve: Where PRRT & Me part ways

In August, I went to see my specialist in Iowa City and was presented with terrible news. The lesions in my liver went to 5% tumor burden in January 2017 to 30% tumor burden in August 2017. PRRT was completely ineffective for me. (Or maybe it was effective and the results could have been worse.) But, my tumor activity was never this active prior to treatment. Doctor O’Dorisio told me